GSK expanding operations in Montgomery County

GSK plans to invest over $800 million to expand its biopharmaceutical operations in Pennsylvania, creating 300 jobs. The project includes a biologics manufacturing facility, R&D pilot plant, and digital technologies, with construction starting in 2027. This follows a previous $800 million investment in the state.

GSK plans to cut up to 1,217 jobs in Belgium as part of a global restructuring to reduce costs by £1.9 billion by 2029. The move aims to streamline operations and focus on high-priority drug pipelines. CEO Luke Miels announced the plan in July to address an upcoming patent cliff for its HIV drug dolutegravir. GSK shares rose 2.6% in line with sector gains.

GSK (LSE:GSK) filed for up to $3.05B in American Depositary Shares. Shares rose 3.59% to £18.16, with 1-year and 5-year returns at 15.52% and 56.52% respectively. Analysts suggest a 16% undervaluation, targeting £21.73, contingent on pipeline success and cost savings. Risks include pricing pressure and slower product ramp-up.

GSK plans to cut 1,217 jobs in Belgium as part of a £1.9 billion cost-cutting initiative to align vaccine production with demand and protect profits ahead of patent expirations, including dolutegravir. The company will maintain most vaccine production and research in Belgium, focusing on high-priority programs like an mRNA flu vaccine, while consulting with unions.

GSK PLC is expected to report Q3 results in line with estimates, with vaccine sales weakness offset by HIV treatments and Nucala. RBC forecasts Q3 revenue of £8.82B, slightly below consensus, and core EPS of 50.8p, matching expectations. The broker maintained its Sector Perform rating and 1,975p price target. GSK is set to report results on 28 October.

Biotech stocks are rebounding due to record pharmaceutical M&A deals, with 37 acquisitions worth at least $1B each in 2026, totaling $216B. Key deals include Vertex (VRTX) acquiring Crinetics (CRNX) for $10B. Institutional investors are bullish, but retail sentiment is low. The Direxion Biotech Bull 3x Shares (LABU) fund has gained 52.5% YTD, despite its index being down last week.